Canaccord Genuity Downgrades Health Catalyst to Hold, Lowers Price Target to $1.8

Benzinga Newsdesk www.benzinga.com Negative 80.6%

Neg 80.6% Neu 0% Pos 0%

Canaccord Genuity analyst Richard Close downgrades Health Catalyst (NASDAQ:HCAT) from Buy to Hold and lowers the price target from $3 to $1.8.